Elestrin is owned by Mylan Speciality Lp.
Elestrin contains Estradiol.
Elestrin has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Elestrin are:
Elestrin was authorised for market use on 15 December, 2006.
Elestrin is available in gel, metered;transdermal dosage forms.
The generics of Elestrin are possible to be released after 25 June, 2022.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7198801||MYLAN SPECIALITY LP||Formulations for transdermal or transmucosal application|| |
(11 months ago)
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 15 December, 2006
Dosage: GEL, METERED;TRANSDERMAL
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic